Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes

Cancers harboring mutations in the Kirsten rat sarcoma homolog (KRAS) gene have been associated with poor prognosis and lack of targeted therapies. KRAS mutations occur in approximately one in four patients diagnosed with non-small cell lung cancer (NSCLC) with KRAS G12C mutations harbored at approx...

Descripción completa

Detalles Bibliográficos
Autores principales: Palma, Gabriela, Khurshid, Faisal, Lu, Kevin, Woodward, Brian, Husain, Hatim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630042/
https://www.ncbi.nlm.nih.gov/pubmed/34845311
http://dx.doi.org/10.1038/s41698-021-00237-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630042/
https://www.ncbi.nlm.nih.gov/pubmed/34845311
http://dx.doi.org/10.1038/s41698-021-00237-5

Ejemplares similares